CA2929123A1 - Amorphous magnesium-substituted calcium phosphate compositions and their uses - Google Patents

Amorphous magnesium-substituted calcium phosphate compositions and their uses Download PDF

Info

Publication number
CA2929123A1
CA2929123A1 CA2929123A CA2929123A CA2929123A1 CA 2929123 A1 CA2929123 A1 CA 2929123A1 CA 2929123 A CA2929123 A CA 2929123A CA 2929123 A CA2929123 A CA 2929123A CA 2929123 A1 CA2929123 A1 CA 2929123A1
Authority
CA
Canada
Prior art keywords
treatment
composition
calcium phosphate
amorphous magnesium
substituted calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2929123A
Other languages
English (en)
French (fr)
Inventor
Jonathan Joseph Powell
Nuno Jorge Rodrigues Faria
Laetitia PELE
Rachel HEWITT
Emma THOMAS-MCKAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Kingdom Research and Innovation
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of CA2929123A1 publication Critical patent/CA2929123A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00—Phosphorus; Compounds thereof
    • C01B25/16—Oxyacids of phosphorus; Salts thereof
    • C01B25/26—Phosphates
    • C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
CA2929123A 2013-11-05 2014-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses Abandoned CA2929123A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1319548.2 2013-11-05
GBGB1319548.2A GB201319548D0 (en) 2013-11-05 2013-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses
PCT/GB2014/053291 WO2015067939A1 (en) 2013-11-05 2014-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses

Publications (1)

Publication Number Publication Date
CA2929123A1 true CA2929123A1 (en) 2015-05-14

Family

ID=49767709

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929123A Abandoned CA2929123A1 (en) 2013-11-05 2014-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses

Country Status (16)

Country Link
US (1) US10596122B2 (enExample)
EP (1) EP3065715B1 (enExample)
JP (2) JP2016537408A (enExample)
KR (1) KR20160079060A (enExample)
CN (1) CN105722504A (enExample)
AU (1) AU2014345334B2 (enExample)
BR (1) BR112016009809A2 (enExample)
CA (1) CA2929123A1 (enExample)
EA (1) EA201690659A1 (enExample)
ES (1) ES2761559T3 (enExample)
GB (1) GB201319548D0 (enExample)
IL (1) IL245380B (enExample)
MX (1) MX367473B (enExample)
SG (2) SG10201803562YA (enExample)
WO (1) WO2015067939A1 (enExample)
ZA (1) ZA201602906B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106660794A (zh) * 2014-05-16 2017-05-10 索尔维公司 用于生产磷酸钙反应物的方法、所获得的反应物以及其在纯化液体排出物中的用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses
KR101893110B1 (ko) * 2016-07-27 2018-08-31 삼일제약 주식회사 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제
EP3538659A4 (en) * 2016-11-09 2020-07-15 Engene, Inc. INTESTINAL EXPRESSION OF THE SCHEDULED DEATH LIGAND 1
CN110573455A (zh) * 2017-04-27 2019-12-13 武礼伟仁株式会社 羟基磷灰石、化妆品和食品及其生产方法
WO2021003601A1 (zh) * 2019-07-05 2021-01-14 广州中大医疗器械有限公司 一种新型可载药微球及其制备方法
WO2021086252A1 (en) 2019-10-30 2021-05-06 Psilox Ab Stabilized amorphous calcium magnesium phosphate particle compositions
CN116768175B (zh) * 2023-07-01 2025-12-19 常州市第二人民医院 高稳定性生物活性无定形磷酸钙镁的制备方法及应用
KR20260019884A (ko) * 2024-08-02 2026-02-10 한국과학기술연구원 레이저를 이용한 아파타이트 분말 연속 합성 장치 및 방법
CN118929595A (zh) * 2024-08-30 2024-11-12 昆明理工大学 稳定型掺镁无定形磷酸钙纳米颗粒的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
US6541037B1 (en) 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
EP1872798B1 (en) 2005-04-06 2013-06-05 Kabushiki Kaisha Sangi Intestinal absorptive anti-tumor agent
EP2106217B1 (en) 2006-12-12 2019-03-13 Firmenich S.A. Active ingredient delivery system with an amorphous metal salt as carrier
US20120128767A1 (en) * 2008-05-01 2012-05-24 Lee William W Therapeutic calcium phosphate particles and methods of making and using same
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106660794A (zh) * 2014-05-16 2017-05-10 索尔维公司 用于生产磷酸钙反应物的方法、所获得的反应物以及其在纯化液体排出物中的用途
CN106660794B (zh) * 2014-05-16 2019-02-12 索尔维公司 用于生产磷酸钙反应物的方法、所获得的反应物以及其在纯化液体排出物中的用途

Also Published As

Publication number Publication date
US10596122B2 (en) 2020-03-24
MX2016005415A (es) 2017-03-01
AU2014345334B2 (en) 2019-10-31
ZA201602906B (en) 2019-09-25
EA201690659A1 (ru) 2016-10-31
MX367473B (es) 2019-08-23
IL245380A0 (en) 2016-06-30
WO2015067939A1 (en) 2015-05-14
ES2761559T3 (es) 2020-05-20
US20160235683A1 (en) 2016-08-18
GB201319548D0 (en) 2013-12-18
IL245380B (en) 2019-02-28
KR20160079060A (ko) 2016-07-05
EP3065715B1 (en) 2019-10-02
AU2014345334A1 (en) 2016-05-19
JP2016537408A (ja) 2016-12-01
BR112016009809A2 (pt) 2017-12-05
EP3065715A1 (en) 2016-09-14
JP2020073467A (ja) 2020-05-14
SG11201603261PA (en) 2016-05-30
SG10201803562YA (en) 2018-06-28
CN105722504A (zh) 2016-06-29

Similar Documents

Publication Publication Date Title
AU2014345334B2 (en) Amorphous magnesium-substituted calcium phosphate compositions and their uses
JP7862013B2 (ja) 免疫応答を調節可能な金属含有製剤のための組成物および方法
JP7812573B2 (ja) 生体高分子薬を送達するための組成物及び方法
KR102717053B1 (ko) 염증 치료용 면역-변형된 입자
JP6199955B2 (ja) 炎症を治療するための方法および組成物
KR102492240B1 (ko) 랑게린+ 세포 표적화
KR20140037789A (ko) 암의 예방 및 치료를 위한 조성물 및 방법
Chen et al. Protecting against postsurgery oral cancer recurrence with an implantable hydrogel vaccine for in situ photoimmunotherapy
Huang et al. Quaternized cationic carbon dots as antigen delivery systems for improving humoral and cellular immune responses
Jiang et al. PEG-grafted arsenic trioxide-loaded mesoporous silica nanoparticles endowed with pH-triggered delivery for liver cancer therapy
Rengaraj et al. PAMAM/5-fluorouracil drug conjugate for targeting E6 and E7 oncoproteins in cervical cancer: a combined experimental/in silico approach
CN118043084A (zh) 用于能够调节免疫应答的含金属制剂的组合物和方法
EP4493209A1 (en) Tumor antigens, compounds comprising the tumor antigens kras, tpx2 or aurka and uses thereof
Nayak et al. Chitosan micro and nanoparticles for delivery of drugs and therapeutic proteins
Bani Hani Effects of Carboxylated Nanodiamonds on Macrophages During and After Differentiation
de Oliveira Conniot Maulticomponente Particulates for Immune Modulation
Hsieh Viral Protein Encapsulation for Vaccine Vehicles: Characterization and in vitro Studies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191017

FZDE Discontinued

Effective date: 20220411